These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28968794)

  • 41. Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.
    Park J; Archuleta S; Oh MH; Shek LP; Wang H; Bonaparte M; Frago C; Bouckenooghe A; Jantet-Blaudez F; Begue S; Gimenez-Fourage S; Pagnon A
    Hum Vaccin Immunother; 2021 Jul; 17(7):2107-2116. PubMed ID: 33626291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes.
    Lecouturier V; Berry C; Saulnier A; Naville S; Manin C; Girerd-Chambaz Y; Crowe JE; Jackson N; Guy B
    Vaccine; 2019 Jul; 37(32):4601-4609. PubMed ID: 29706291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
    Scott LJ
    Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
    Coronel-Martinez DL; Park J; López-Medina E; Capeding MR; Bonfanti AAC; Montalbán MC; Ramírez I; Gonzales MLA; Zambrano B; Dayan G; Chen Z; Wang H; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2022 Jun; 22(6):901-911. PubMed ID: 35364022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dengue vaccination during pregnancy - An overview of clinical trials data.
    Skipetrova A; Wartel TA; Gailhardou S
    Vaccine; 2018 May; 36(23):3345-3350. PubMed ID: 29716774
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis.
    Rosa BR; Cunha AJLAD; Medronho RA
    BMJ Open; 2019 Mar; 9(3):e019368. PubMed ID: 30872537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4-5 Years After a Primary 3-Dose Schedule.
    Coronel D; García-Rivera EJ; Rivera M; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Zhao J; Tila M; Jackson N; Zambrano B; Noriega F
    Pediatr Infect Dis J; 2019 May; 38(5):e90-e95. PubMed ID: 30986790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States.
    Glass A; Polhemus M; Wang D; Jarman RG; Thomas SJ; Friberg H; Currier JR; Bonaparte M; De La Barra R; Princiotta MF; Abbott M; Cuzzo B; Machabert T; Sridhar S; Endy TP
    J Infect Dis; 2020 Mar; 221(7):1057-1069. PubMed ID: 31755526
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
    Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
    Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.
    Chu H; George SL; Stinchcomb DT; Osorio JE; Partidos CD
    J Infect Dis; 2015 Nov; 212(10):1618-28. PubMed ID: 25943203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.
    Dayan GH; Garbes P; Noriega F; Izoton de Sadovsky AD; Rodrigues PM; Giuberti C; Dietze R
    Am J Trop Med Hyg; 2013 Dec; 89(6):1058-1065. PubMed ID: 24189367
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
    Guy B; Briand O; Lang J; Saville M; Jackson N
    Vaccine; 2015 Dec; 33(50):7100-11. PubMed ID: 26475445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9-13 Years of Age in Malaysia: A Phase IIIb, Randomized, Open-label Study.
    Hassan J; Toh TH; Sivapunniam SK; Hasim R; Ghazali NF; Sulaiman S; Koh MT; Meyer S; Toh ML; Zocchetti C; Vigne C; Mascareñas C
    Pediatr Infect Dis J; 2021 Aug; 40(8):774-781. PubMed ID: 34250977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review.
    Agarwal R; Wahid MH; Yausep OE; Angel SH; Lokeswara AW
    Acta Med Indones; 2017 Jan; 49(1):24-33. PubMed ID: 28450651
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
    Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R
    Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
    Plennevaux E; Moureau A; Arredondo-García JL; Villar L; Pitisuttithum P; Tran NH; Bonaparte M; Chansinghakul D; Coronel DL; L'Azou M; Ochiai RL; Toh ML; Noriega F; Bouckenooghe A
    Clin Infect Dis; 2018 Apr; 66(8):1164-1172. PubMed ID: 29300876
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.
    Gilbert PB; Huang Y; Juraska M; Moodie Z; Fong Y; Luedtke A; Zhuang Y; Shao J; Carpp LN; Jackson N; Chambonneau L; Bouckenooghe A; Zambrano B; Frago C; Pallardy S; Noriega F
    Am J Trop Med Hyg; 2019 Jul; 101(1):164-179. PubMed ID: 31115304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.